AbbVie reported that Botox sales beat estimates in Q2, marking a notable inflection after a prolonged period of market headwinds. The revival reflects several converging factors: stabilization of the U.S. aesthetic market after GLP-1 disruption, successful defense against Evolus' Jeuveau price compression, and renewed demand from practices managing post-weight-loss patients seeking facial rejuvenation.
The strength arrives as AbbVie pursues FDA approval for a new masseter indication—a move that could unlock an adjacent patient population and differentiate Botox from generic competitors. For practice owners, the data suggests toxin pricing may have found a floor, and that volume recovery is possible if patient acquisition strategies account for the GLP-1 demographic shift.